secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K/A
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001558370-23-019624
Event type: m_and_a
Sentiment:  negative
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony files Zynerba FY2022 audited financials; net loss $35M, accumulated deficit $274.5M
--------------------------------------------------------------------------------

- Zynerba FY2022 net loss $35.0M ($0.82 loss per share); no revenue; R&D expense $21.1M, G&A $14.2M.
- Cash and equivalents $50.6M at Dec 31, 2022; sufficient to fund operations to mid-2024 per management.
- Acquisition closed Oct 10, 2023; pro forma combined statements filed as Exhibit 99.3 (not included in this text).
- Zynerba clinical-stage pipeline targets FXS and 22q deletion syndrome; deferred Phase 3 ASD program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023019624/0001558370-23-019624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023019624/hrmy-20231010x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer